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Increased expression of tumour-associated trypsin inhibitor (TATI) in tumour tissue and/or serum has been associated with poor
survival in various cancer forms. Moreover, a proinvasive function of TATI has been shown in colon cancer cell lines. In this study,
we have examined the prognostic significance of tumour-specific TATI expression in colorectal cancer, assessed by
immunohistochemistry (IHC) on tissue microarrays (TMAs) with tumour specimens from two independent patient cohorts.
Kaplan–Meier analysis and Cox proportional hazards modelling were used to estimate time to recurrence, disease-free survival and
overall survival. In both cohorts, a high (450% of tumour cells) TATI expression was an independent predictor of a significantly
shorter overall survival. In cohort II, in multivariate analysis including age, gender, disease stage, differentiation grade, vascular invasion
and carcinoembryonal antigen (CEA), high TATI expression was associated with a significantly decreased overall survival (HR¼1.82;
95% CI¼1.19–2.79) and disease-free survival (HR¼1.56; 95% CI¼1.05–2.32) in curatively treated patients. Moreover, there was
an increased risk for liver metastasis in both cohorts that remained significant in multivariate analysis in cohort II (HR¼2.85; 95%
CI¼1.43–5.66). In conclusion, high TATI expression is associated with liver metastasis and is an independent predictor of poor
prognosis in patients with colorectal cancer.
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Tumour invasion of surrounding tissue requires degradation of the
basal membrane and extracellular matrix (Kohn and Liotta, 1995).
Matrix metalloproteinases (MMPs) and matrix serine proteases
(MSPs) are two groups of proteolytic enzymes that are proposed to
be the most important for tumour progression (Stenman, 1990;
Mignatti and Rifkin, 1993; Nelson et al, 2000). Trypsin is a potent
MSP protease that hydrolyses a variety of proteins and activates
other MSPs and MMPs (Koivunen et al, 1991; Yamamoto et al,
2003). Four identical isoforms of trypsinogen have been described
in human tissue and these isoforms are homologous (Emi et al,
1986; Tani et al, 1990; Wiegand et al, 1993; Koshikawa et al, 1998).
In the gastrointestinal tract, the main function of the trypsin is to
break down dietary proteins. It is expressed by many tumours
and also plays a significant role in tumour invasion (Koivunen
et al, 1991; Moilanen et al, 2003; Paju et al, 2004). Immunohis-
tochemical (IHC) expression of trypsin in colorectal cancer (CRC)
correlates with unfavourable clinicopathological characteristics
and shortened survival (Yamamoto et al, 2003).
The tumour-associated trypsin inhibitor (TATI), synonymous
with serine protease inhibitor Kazal type 1 (SPINK1) and
pancreatic secretory trypsin inhibitor (PSTI; Huhtala et al, 1982),
balances and inhibits trypsin specifically and may thus reduce
tissue destruction (Wiksten et al, 2005). It is also a weak inhibitor
of other serine proteinases (Fritz et al, 1967; Huhtala et al, 1982;
Turpeinen et al, 1988). In vitro, TATI increases cell migration and
plays a role in tissue repair (Stenman, 1990). It has been suggested
that expression of TATI and trypsin is balanced in normal tissue,
but this balance could be disrupted during tumour progression
(Hotakainen et al, 2006).
Tumour-associated trypsin inhibitor expression has been
associated with impaired survival in several forms of cancer
(Stenman, 2002; Paju et al, 2004; Lee et al, 2007) but not in gastric
cancer, where it is believed to have a natural function of protecting
the mucosa from proteolytic degradation (Freeman et al, 1990;
Playford et al, 1991; Marchbank et al, 1996, 1998; Wiksten et al,
2005). However, in most cancer forms, TATI and trypsin are
coexpressed and show similar and adverse associations to disease
outcome (Paju et al, 2004; Hotakainen et al, 2006).
Elevated serum TATI has been shown to be a prognostic marker
for ovarian cancer (Venesmaa et al, 1994, 1998), kidney cancer
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s(Paju et al, 2001) and bladder cancer (Kelloniemi et al, 2003). In
ovarian carcinoma, TATI expression, both in tissue and serum, has
been associated with a shorter survival and high tissue expression
was the most useful prognostic factor (Huhtala et al, 1982; Paju
et al, 2004).
Coexpression of trypsin and TATI has previously been found at
both mRNA and protein level in CRC (Solakidi et al, 2003), but we
are not aware of any published reports on the association between
expression of TATI in tumour tissue and survival in patients with
CRC. However, a recent study showed that TATI is associated with
autocrine induction and metastasis in colon cancer cells (Gouyer
et al, 2008).
The purpose of this study was to analyse the association between
IHC expression of TATI in CRC and clinicopathological
parameters, its recurrence and survival.
PATIENTS AND METHODS
Cohort I
Cohort I includes 118 cases of CRC, 61 (52%) women and 57 (48%)
men, diagnosed at the Department of Pathology, Malmo ¨ University
Hospital, between January 1999 and March 2002. This cohort was
designed as an initial screening cohort for tissue biomarkers of
potential diagnostic or prognostic relevance. Therefore, the cases
were selected to obtain an equal distribution of disease stages
I–III, with 35 patients in stage I, 42 patients in stage II, 35 patients
in stage III and 6 patients in stage IV. Median age at diagnosis was
75 years (range: 32–88; mean 73), and after a median follow-up of
85 months (0–115) (mean 56), 54 patients (46%) were alive and 64
(54%) were dead. Information on treatment was not available for
this cohort. Data on overall survival (OS) were collected from the
population register. Approval was obtained from the Ethics
committee at the Lund University (cohort I, ref no. 447–07),
whereby informed consent was deemed not to be required other
than by the opt-out method.
Cohort II
The second cohort, used as a validation cohort, consists of 320
prospectively collected patients undergoing elective surgery for
CRC at the Central District Hospital in Va ¨stera ˚s, Sweden, between
June 2000 and December 2003, 277 (87%) of which were treated
surgically with curative intent. Information on cancer recurrence,
death and cause of death were obtained by matching with the
Regional Oncology Registry and from the hospital records. Median
follow-up time was 6 years (4–7) for surviving patients. Recurrent
disease was reported for 54 (19%) of curatively treated patients,
and 119 (37%) patients died during the study period. Preoperative
radiotherapy was given to 84/108 patients with rectal cancer. All
patients o75 years with colon cancer stage III (n¼36) and 22 of
29 rectal cancer patients as well as some patients with high risk
(T4, low differentiation) stage II disease (13/71) received adjuvant
chemotherapy. Palliative chemotherapy was given in 23 of 27
patients o75 years with stage IV disease. More than 12 lymph
nodes were examined in 224 (70%) of 320 patients and in 96 (73%)
of 132 patients with stage II disease. Ethical approval was obtained
from the Ethics committee at Uppsala University (cohort II, ref no.
00–001). All patients included in this cohort gave their informed
consent for participation in the study.
Tissue microarray (TMA) construction
Tissue microarrays were constructed as described earlier
(Kononen et al, 1998). In brief, 2 1mm cores from areas
representative of invasive cancer were sampled for each case and
mounted in a recipient block using a manual arraying device
(MTA-1; Beecher Instruments, Hartland, WI, USA). In addition, a
number of samples from normal colonic mucosa, adenomas and
lymph node metastases were included in the TMA from cohort II.
Immunohistochemistry
In all, 4mm sections were dried, deparaffinised, rehydrated,
and heat-mediated antigen retrieval was carried out by
boiling under pressure in DAKO Target Retrieval Buffer (DAKO,
Glostrup, Denmark; pH 9.0). Immunohistochemistry was carried
out in the DAKO Techmate 500 system (DAKO) using a mono-
clonal anti-TATI antibody (6E8) diluted 1:500 as described earlier
(Osman et al, 1993).
Tumour-associated trypsin inhibitor was expressed in the
cytoplasm and the percentage of positive tumour cells in each
core was estimated and assigned values of 0, 5 or multiples of 10%.
The intensity of the expression was assigned a value of 0, 1, 2 or 3.
Figure 1 Immunohistochemical images of invasive cancer with high (A) and low (B) tumour-associated trypsin inhibitor (TATI) score and expression of
TATI in adjacent non-malignant mucosa (C).
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the core with the highest percentage of positive cells/‘best score’
(Tomlins et al, 2008) and mean score were denoted. Samples from
adjacent normal mucosa and adenomas were scored in the same
fashion. The IHC staining was evaluated independently by two of
the authors (AG and KJ) who were blinded to clinical and outcome
data. Scoring differences were discussed to reach consensus.
Statistics
The w
2 and Spearman’s correlation tests were used for comparison
of TATI expression and relevant patient and tumour character-
istics. The Kaplan–Meier method and log-rank test were used to
estimate disease-free survival (DFS), time to recurrence (TTR) and
OS. End points were defined as recommended by Punt et al (2007);
OS was measured from the date of surgery to the date of death; the
observations were censored at the end of the study period
(1 November 2008). Disease-free survival was measured in
curatively treated patients from the date of surgery to the date of
second cancer, recurrence or death from any cause. Time to
recurrence was measured in curatively treated patients from the
date of surgery to the date of locoregional recurrence, distant
metastases or to the date of death in CRC; the observations were
censored at the end of the study period or at the date of death in
non-CRC. A Cox proportional hazards model/hazard ratios (HRs)
was used for estimation of relative risks in both univariate and
multivariate analyses, and adjusted for age, gender, disease stage,
differentiation grade and lymphatic or vascular invasion. All
statistical tests were two-sided and P-values o0.05 were
considered significant. Calculations were carried out with either
SPSS15.0 (SPSS Inc., Chicago, IL, USA) or Statistica 7 (Stat Soft
Inc., Tulsa, OK, USA).
RESULTS
Tumour-associated trypsin inhibitor expression in normal
colonic mucosa, cancer and metastases
Tumour-associated trypsin inhibitor was expressed in the
cytoplasm both in the normal mucosa, the primary cancer and
metastases (Figure 1). The overall staining distribution (best score)
in cancer cells was similar in cohorts I and II (data not shown).
Table 1 Correlation betweeen TATI expression and clinicopathological parameters in two colorectal cancer cohorts
Cohort I Cohort II
TATI fraction 0–50% 450% 0–50% 450%
n (%) 90 (76.3) 24 (20.3) P-value* 241 (78.0) 68 (22.0) P-value*
Age
p75 50 (55.6) 6 (25.0) 143 (59.3) 33 (48.5)
475 40 (44.4) 18 (75.0) 0.008 98 (40.7) 35 (51.5) 0.112
Gender
Female 49 (54.4) 9 (37.5) 120 (49.8) 32 (47.1)
Male 41 (45.6) 158 (62.5) 0.143 121 (50.2) 36 (52.9) 0.691
Tumour (T) stage
1 9 (3.7) 3 (4.4)
2 28 (11.6) 12 (17.6)
3 156 (64.7) 47 (69.1)
4 48 (19.9) 6 (8.8) 0.142
Lymph node (N) stage
0 50(55.6) 14(58.3) 138 (57.3) 42 (61.8)
1 19(21.1) 6(25.0) 46 (19.1) 16 (23.5)
2 8(8.9) 1(4.2) 0.65 57 (23.7) 10 (14.7) 0.302
No information 13(14.4) 3(12.5)
Disease stage
I 24 (26.7) 11 (45.8) 31 (12.9) 13 (19.1)
II 35 (38.9) 5 (20.8) 101 (41.9) 26 (38.2)
III 28 (31.1) 5 (20.8) 75 (31.1) 23 (33.8)
IV 3(3.3) 3(12.5) 0.277 34 (14.1) 6 (8.8) 0.305
Differentiation grade
High–moderate 73 (81.1) 21 (87.5) 186 (77.2) 55 (80.9)
Poor 17 (18.9) 3 (12.5) 0.46 55 (22.8) 13 (19.1) 0.515
Vascular invasion
No invasion 78 (86.7) 21 (87.5) 209 (86.7) 59 (86.8)
Invasion 12 (13.3) 3 (12.5) 0.915 32 (13.3) 9 (13.2) 0.993
CEA
o6ngml
 1 158 (65.6) 53 (77.9)
X6ngml
 1 73 (30.3) 13 (19.1)
No information 10 (4.1) 2 (2.9) 0.061
TATI¼tumour-associated trypsin inhibitor. *w
2-test of association was used for 2 2 tables and w
2-test for linear trend for tables with more than two rows and/or columns. The
number of cases with missing data is given for some variables, but these are not included in the analyses.
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the paired tissue cores from each individual tumour, that is, no
difference between mean and best scores (data not shown). Using
cohort I as a test cohort to construct a dichotomised variable for
defining TATI high and low cases, we compared different
thresholds (1, 25, 50 and 75% positive cells) with respect to their
impact on survival. High TATI expression was associated with a
shorter survival for all cutoffs tested (data not shown), but the
most significant separation was observed at 50%. The staining
intensity had no impact on survival. By this approach, the
proportion of cases with low and high expression was similar in
both cohorts with 24 cases (20.3%) in cohort I and 66 cases
(19.9%) in cohort II exhibiting high TATI expression. No
differences were seen in the expression of TATI best score in
different preoperative radiation therapy groups in rectal cancer
patients (data not shown).
Correlation between TATI expression and
clinicopathological parameters
The distribution of tumours with low and high TATI expression in
relation to tumour and patient characteristics is shown in Table 1.
In cohort I, high TATI expression was only significantly associated
with age (P¼0.008). In cohort II, lower expression was seen with
advanced tumour (T), lymph node (N) and disease stage, also
visualised in Figure 2. There was a significant association between
a lower TATI fraction (0–50%) and higher tumour stage (P¼018).
In cohort II, TATI was expressed in 89 (86%) of 104 samples from
benign mucosa and in 12 (18%) of 67 lymph node metastases.
When right and left colonic tumours were compared with left
colonic cancers, defined as tumours in the splenic flexure to the
rectum, a trend for lower expression of TATI best score was
seen in left colonic cancers. Tumour-associated trypsin inhibitor
best score p50 was seen in 141 of 188 (0.75%) left colonic cancers
compared with 100 out of 121 (0.83%) right colonic cancers
(P¼0.113, w
2-test).
Tumour-associated trypsin inhibitor expression in relation
to survival and metastasis
In cohort I, tumours with more than 50% TATI-expressing tumour
cells had a significantly shorter OS (HR¼2.42; 95% CI¼ 1.38–
4.26, P¼0.002). This association remained significant in
multivariate analysis after adjustment for established clinicopatho-
logical parameters (HR¼1.80; 95% CI¼ 0.99–3.27; P¼0.05).
There was a significant association with the appearance of liver
metastases (HR¼3.97; 95% CI¼0.99–15.88; P¼0.05) in
univariate, but not in multivariate analysis, including age,
gender, disease stage, differentiation grade and vascular invasion
(HR¼ 3.69; 95% CI¼ 0.87–15.67; P¼0.08).
In cohort II, patients with high TATI score had a significantly
shorter OS and DFS, compared to those with low fraction, in
curatively treated patients (Figure 3). This association remained
significant in multivariate analysis, including adjustment for age,
gender, disease stage, differentiation grade, vascular invasion and
carcinoembryonal antigen (CEA; Table 2).
Furthermore, patients with a high fraction of TATI-positive cells
in primary tumour tissue tended to have increased risk of cancer
recurrence (Figure 4a) and an increased risk of liver metastasis
(Figure 4b), and this was significant also in multivariate analysis
(HR¼2.85; 95% CI¼1.43–5.66).
As mentioned earlier most of the patients (n¼40) with
metastatic disease at diagnosis had TATI best score o50%
(n¼34; 85%) (Figure 2b); however, there was a trend towards
more synchronous liver metastases in those with TATI 450% (5 of
6; 83%) compared with TATIo50% in primary tumour tissue
(16 of 34; 47%; P¼0.101).
DISCUSSION
Our results show that tumour-specific TATI expression is
associated with shorter survival of patients with CRC. These
findings were observed in two independent patient cohorts. These
results are in line with recent in vitro data (Gouyer et al, 2008).
Furthermore, in both cohorts, there was a significant asso-
ciation between TATI expression and metastasis to the liver and
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Figure 2 Tumour-associated trypsin inhibitor (TATI) best score for
fraction of immunoreactivity in primary tumour tissue from patients with
colorectal cancer and its relation to tumour (T) (A), disease (B) and to
lymph node (N) stages (C). Boxes indicate mean (small central box)
and mean ±1s.e. (larger box). Whiskers indicate mean ±1.96 times s.e.
Kruskal–Wallis test was used for comparison.
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sin cohort II; representing a larger number of patients, this
association remained significant in multivariate analysis.
An elevated TATI expression has, with few exceptions, been
associated with a more aggressive tumour phenotype and poor
clinical outcome in several forms of cancer (Paju et al, 2004, 2007;
Hotakainen et al, 2006; Lee et al, 2007; Tomlins et al, 2008). Given
the frequently observed coexpression of TATI and trypsin in
cancer, it can be hypothesised that increased levels of TATI reflect
a simultaneous elevation of trypsin and, hence, increased
propensity of the tumour cells to invade and spread. However,
in prostate cancer, TATI may actually be an independent mediator
of aggressive disease (Tomlins et al, 2008). The mechanisms by
which TATI is associated with aggressive cancer need to be further
explored. Although protease inhibitors could be expected to
control the invasion-promoting effects of various proteases, there
is increasing evidence showing that overexpression of various
protease inhibitors results in enhanced malignancy of cancer cells.
For instance, a number of studies have shown that increased serum
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Figure 3 Overall survival (A) and disease-free survival (B) in curatively treated patients with colorectal cancer in cohort II according to high (n¼61)
versus low (n¼205) TATI best score (cutoff ¼50% positive cells).
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sconcentrations of tissue inhibitor of metalloproteinases 1 (TIMP-1),
a major inhibitor of metalloproteinases, often is associated with
a poor clinical outcome in various cancer forms (Ree et al, 1997;
Holten-Andersen et al, 1999; Schrohl et al, 2004; Yukawa et al,
2004). Similarly, another protease inhibitor, the plasminogen
activator inhibitor 1 (PAI-1) has been shown to be associated with
poor prognosis in breast cancer (Grondahl-Hansen et al, 1993),
lung cancer (Pedersen et al, 1994) and CRC (Nielsen et al, 1998).
Overexpression of secretory leukocyte protease inhibitor (SLPI),
which also inhibits trypsin, increases the malignant properties of
lung cancer cell lines (Devoogdt et al, 2003).
So far, the mechanisms by which TATI is associated with
tumour aggressiveness are unknown, but because no TATI
receptor has been identified and TATI is a very specific trypsin
inhibitor (Turpeinen et al, 1988), it is tempting to speculate that
TATI exerts its effect through modulation of trypsin activity.
Trypsin may affect various cellular functions, for example,
proliferation and invasion, by activating protease-activated
receptors (PARs) and especially PAR-2 (Soreide, 2008).
The complexity of the interplay and diverging actions of
proteases and their inhibitors in human cancer is further
illustrated by the fact that experimental targeted therapies with
synthetic proteinase inhibitors have not proven effective and have,
in some trials, even elicited poorer results and more adverse effects
than standard chemotherapy (Kruger et al, 2001; Coussens et al,
2002; Moore et al, 2003).
Furthermore, treatment with the synthetic MMP inhibitor,
batimastat, has been shown to make breast cancer and lymphoma
cells more prone to form liver metastases in mouse models (Kruger
et al, 2001). In addition, batimastat treatment induced the
expression of MMPs, metastasis-promoting and angiogenesis
factors in the liver (Kruger et al, 2001). This is particularly
interesting in the light of our findings of a significant association
between TATI expression and metastasis to the liver. A link
between TATI and metastatic disease has also been shown in CRC
cell lines and downregulation of TATI resulted in a concomitant
downregulation of several metastasis-associated genes (Gouyer
et al, 2008).
Another explanation for the more malignant phenotype
associated with TATI overexpression could be that an increased
expression of proteinase inhibitors may help the tumour cells
evade the immune response and make them better equipped for
survival and distant spread. It has been suggested that the
increased expression of proteinases associated with malignant
disease may, to a large extent, be because of an immunological host
response induced by the tumour (Nelson et al, 2000). For instance,
in breast cancer cells, stromelysin-3, a proteinase from the MMPs
family, has been found exclusively in stromal cells surrounding
neoplastic invasive cells, but not non-invasive cells (Basset et al,
1990).
Tumour-associated trypsin inhibitor is believed to play a
protective role in both gastric mucosa (Wiksten et al, 2005) and
colonic mucosa (Soreide et al, 2006) and in accordance with these
findings, we found that TATI was highly expressed in non-
malignant colonic mucosa. It should, however, be pointed out that
the non-malignant mucosa studied here had been sampled from
areas adjacent to the tumour and, hence, it cannot be ascertained
whether this truly reflects TATI levels in normal mucosa from
healthy individuals.
In cohort II, there was a significant association between lower
TATI expression and a more advanced tumour stage. Such an
association has previously been found in a small cohort of bladder
Table 2 The relative risks for death in curatively treated patients with colorectal cancer from cohort II
Relative risk for death (overall survival)
Relative risk for second cancer, recurrence or death to any
cause in curatively treated patients (disease-free survival)
Univariate Multivarite Univariate Multivariate
n HR (95% CI) HR (95% CI) n HR (95% CI) HR (95% CI)
Age at operation
Age o75 years 154 1.0 (ref) 1.0 (ref) 154 1.0 (ref) 1.0 (ref)
Age X75 years 123 2.39 (1.62–3.52) 2.74 (1.83–4.09) 123 1.87 (1.32–2.65) 2.09 (1.46–3.0)
Gender
Female 137 1.0 (ref) 1.0 (ref) 137 1.0 (ref) 1.0 (ref)
Male 140 0.78 (0.53–1.14) 0.74 (0.50–1.09) 140 0.81 (0.57–1.15) 0.79 (0.55–1.12 )
Disease stage
Stage I 45 1.0 (ref) 1.0 (ref) 45 1.0 (ref) 1.0 (ref)
Stage II 131 1.09 (0.58–2.02) 1.18 (0.62–2.24) 131 1.57 (0.85–2.87) 1.64 (0.88–3.05)
Stage III 100 1.45 (1.07–1.97) 1.55 (1.13–2.13) 100 1.62 (1.20–2.19) 1.69 (1.24–2.31)
Differentiation grade
High–moderate 221 1.0 (ref) 1.0 (ref) 221 1.0 (ref) 1.0 (ref)
Poor 56 1.40 (0.90–2.20) 1.36 (0.87–2.15) 56 1.38 (0.88–2.17) 1.30 (0.86–1.96)
Lymphatic or vascular vessel invasion
No invasion 252 1.0 (ref) 1.0 (ref) 252 1.0 (ref) 1.0 (ref)
Invasion 25 1.68 (0.94–3.01) 1.64 (0.90–2.99) 25 1.93 (1.15–3.21) 1.73 (1.02–2.94)
CEA
o6ngml
 1 204 1.0 (ref) 1.0 (ref) 277 1.0 (ref) 1.0 (ref)
46ngml
 1 62 1.41 (0.92–2.17) 1.35 (0.88–2.09) 0 1.56 (1.06–2.29) 1.48 (1.00–2.20)
TATI fraction of immunorectivity best score
o50% 205 1.0 (ref) 1.0 (ref) 205 1.0 (ref) 1.0 (ref)
450% 61 1.73 (1.14–2.64) 1.82 (1.19–2.79) 61 1.52 (1.03–2.25) 1.56 (1.05–2.32)
CI¼confidence interval; CEA¼carcinoembryonal antigen; HR¼hazard ratio; TATI¼tumour-associated trypsin inhibitor. Uni- and multivariate analyses, including age, gender,
disease stage, differentiation grade, lymphatic or vascular vessel invasion, CEA and TATI fraction of immunoreactivity best score.
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scancer (Hotakainen et al, 2006) where high TATI expression
tended to be associated with a better prognosis. There was also a
trend, however non-significant, towards a lower TATI expression
in more advanced disease stages; but the proportion of synchro-
nous liver metastases was higher in cases with TATI 450%.
Further studies are warranted to investigate which cutoffs are
the most appropriate for defining high versus low TATI
expression. In this study, we first analysed TATI expression in a
retrospectively collected cohort and established a dichotomised
variable with the best prognostic separation. This cutoff also
proved to have a prognostic impact in a second cohort with
prospectively collected tumour samples, in which the risk of
sampling bias should be reduced. In neither of the cohorts did the
staining intensity have any impact on prognosis, only the fraction
of positive cells. As the staining intensity is often more easily
affected by the variability of sample preparation, particularly the
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Figure 4 Time to recurrence (A) and recurrence of liver metastasis (B) in curatively treated patients with colorectal cancer in cohort II according to high
(n¼61) versus low (n¼205) TATI best score (cutoff¼50% positive cells).
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stime of fixation in formalin, the fraction of positive cells might be a
more reliable parameter with better reproducibility. Both para-
meters should, however, be taken into account in future studies
evaluating TATI expression by IHC, and automated image analysis
may be a more objective approach (Brennan et al, 2008; Rexhepaj
et al, 2008). Other cutoffs, with or without taking the staining
intensity into account, have been used in earlier studies on other
cancer forms, (Paju et al, 2004; Tomlins et al, 2008).
It will also be of interest to investigate the utility of serum TATI as
a prognostic marker and predictor of liver metastasis in CRC.
However, TATI as well as CEA in serum has not proven to correlate
with the absence or presence of metastases or monitoring of disease
after surgery (Catarino and Conde, 1991; Pasanen et al,1 9 9 5 ) .
In conclusion, our results show that tumour-specific over-
expression of TATI contributes to a poor prognosis in CRC and
seems to promote a tumour phenotype with predilection of liver
metastasis in vivo. Thus, therapeutic targeting of TATI could prove
to be an efficient strategy in the management of high-risk CRC
patients.
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